Work

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Year: 2019

Type: conference-abstract

Source: Clinical Trials

DOI: 10.1158/1538-7445.sabcs18-ct032

Authors: Helena Yu, Myung-Ju Ahn, Sang-We Kim, Byoung Chul Cho, Lecia Sequist, Sergey Orlov, Lone H. Ottesen, Remy B. Verheijen, Anders Mellemgaard, Jonathan Wessen, Ji-Youn Han

Institutions: Memorial Sloan Kettering Cancer Center, Samsung Medical Center, Asan Medical Center, Yonsei University, Yonsei Cancer Hospital, Massachusetts General Hospital, AstraZeneca (United Kingdom), National Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4245213665

Cites:

Cited by: 2

Related to: 10